1

June 2016

CLPT: TASE

1

2

Forward looking statements

The following overview contains forward-looking

statements that include, but are not limited to, projections

about our business and our future revenues, expenses

and profitability. Forward-looking statements involve

known and unknown risks, uncertainties and other factors

which may cause the actual events, results, performance,

circumstances or achievements of the Company to be

materially different from those expressed or implied by

such forward-looking statements due to factors that

include, but are not limited to: (1) our ability to develop and

bring to market new products (2) our ability to successfully

complete any necessary or required pre-clinical and/or

clinical studies with our products, if so requires (3) our

ability to receive regulatory clearance or approval to

market our products, if so requires, including due to

changes in regulatory environment (4) our success in

implementing our sales, marketing and manufacturing

plans (5) the level of adoption of our products by medical

practitioners (6) the emergence of other products that may

make our products obsolete (7) protection and validity of

patents and other intellectual property rights and (8) the

effect of competition by other companies and/or

technologies.

You are cautioned not to place undue reliance on these

forward-looking statements, which speak only as of the

date of this overview.

In order to have a comprehensive understanding and

information over the Company, including the risks its

activity is subject to, you must review the Company's

Immediate and Periodical reports (in Hebrew) with the

Israeli Security Authority and the Tel Aviv Stock Exchange

and with the OTCQX and Company's web site (in English).

The Company undertakes no obligation to update any

forward-looking statements, to report events or to report

the occurrence of unanticipated events that may lead to

the actual events, results, performance, circumstances or

achievements of the Company being different than as

envisaged by such forward looking statements.

This overview by no means establishes an offer to

purchase or sale the Company's securities nor an

invitation to receive such offer and is intended for

informative purposes only.

3

Overview

We are a clinical stage regenerative medicine company focused on developing and

commercializing high value tissue repair products intended to accelerate healing

while reducing inflammation and pain

Our products are based on our proprietary plant-based technology for the production

of type I recombinant human collagen (rhCollagen)

We are initially focused on the orthobiologics and advanced wound care markets

The worldwide market opportunity for our initial product candidates exceeds $5 billion

Two products (tendons, wounds) expected to commence sales in Europe this year

(Vergenix FG received CE Mark in February 2016)

Co-developing a bone void filler with a leading US strategic collaborator

to address a multi-billion dollar opportunity in spine and trauma

Listed in Tel-Aviv Stock Exchange (TASE:CLPT)

4

Yehiel Tal

CEO

• Regentis

Biomaterials

• ProChon Biotech

• Kulicke & Soffa

Industries

Oded Shoseyov

Prof./Founder/CSO

• Pauli Clean Tech

• CBD Tech.

• Fulcrum-SPD

• Melodea

• Hebrew University

Eran Rotem

CFO

• Tefron (ex

NYSE,TASE)

• Healthcare Tech.

(NASDAQ)

&Gamida

• E&Y

Experienced

management team

Nadav Orr, PhD

VP R&D

• Ethicon

Biosurgery,

Johnson &

Johnson

Ilan Belzer

COO

• BioHarvest

• Proteologics Ltd.

• OmrixBiopharmaceuticals

• Interpharm

Philippe

Bensimon

VP RA/QA/CA

• Maquet-Getinge

• 3M Medical

Shomrat Shurtz

Senior Director BD

• Protalix

• BBDO Proximity

• Clal holdings

4

5

Avram Hershko,

Prof.

Nobel Laureate

(Chemistry)

Technion

Arthur Gertzman

Bone void fillers,

polymers

Ex MTF

Scott Rodeo, MD

Rotator cuff

Hospital for Special

Surgery

Scientific & clinical

advisors

Ofer Levy, MD

Shoulder and

elbow

Royal Berkshire

hospital

Vicki Rosen, Prof.

Musculoskeletal

regeneration

Harvard

Abhay Pandit,

Prof.

Biomaterials, tissue

engineering

University of

Ireland

Gabi Agar, MD

ACL, cartilage,

meniscus

Assaf Harofeh

Hospital

Thomas Serena,

MD

Penn North

Centers

for Advanced

Wound Care

Joseph M. Lane,

MD

Connective tissue

repair

Hospital for Special

Surgery

6

P4Hα

P4Hβ

LH-3

Post translational

modifications

Col1α1

Col1α2

n- Propeptide c-Propeptide

Stable production

in tobacco plantStructural genes Enzyme genes

CollPlant’s technology: co-expression in plantsof 5 human genes essential for the productionof functional type I human recombinant Collagen

6

7

J.H.-C. Wang / Journal of Biomechanics 39 (2006) 1563–1582

Bones

Skin

Tendons

Ligaments

Collagen

fibril

Collagen

molecule

Collagen

fiber

Primary

fiber bundle

(subfascicle)

Secondary

fiber bundle

(fascicle)

Tertiary

fiber bundle

Tendon unit

α2 α1

Fibroblast

Endotenon

Epitenon280 nm

64 n

1 nm 100 nm 1-20 μm 20-200 μm 500 μm

Collagen is the most basic

building block

7

8

Clear advantages over tissue-extracted collagen

Better bio-functionalityAccelerates primary humancell proliferationFaster tissue healing

Plant-derived rhCollagen

Superior homogeneityUniquely strong and aligned structures, reproducible & thermally stable

Improved safety and greater purityNon-allergenic

Non-immunogenic

No pathogens

Novel applicationsIdeal building block for products with unique properties (e.g. BioInk)

8

9

What is out there today and its limitations?9

D-banding

TISSUE-EXTRACTED PLANT-DERIVED

Fully functional 3-D matrix

Thin fibers/high surface area

Slow cell proliferation and

slow tissue repair

• Foreign body response

• Edema

• Inflammation

Partial

D-banding

Partially functional 3-D matrix

Thick fibers/low surface area

Fast cell proliferation

and fast tissue repair

Cell binding domains Cell binding domains

rhCollagen

• Perfect triple helix

• High cell binding domains

Collagen

• Partially denatured (crosslinked)

• Low cell binding domains

10Scalable production process

GROWING EXTRACTIONPURIFICATION

& FILLINGEND PRODUCTFABRICATION

Clean room facilityLow cost space

Leaves Pellet Collagen

11

Sheets Fibers 3DP BioInk Microspheres

Putty Malleable Paste Flowable gel

Knitted meshes Non-woven meshes rhCollagen meshesrhCollagen coated polymeric fibers

Underlying technology supports a large portfolioof high-value tissue repair products

Source: WFIRM

Collagen configurations

Compounds & composites

Fibers & textiles

12

The lead product candidates

& trauma

Bone void filler Soft Tissue Repair Matrix Wound filler

Wound careOrthopedics

12

13

Soft Tissue Repair matrix

rhCollagen/PRP matrix

Enables controlled release of growth factors and serves as scaffold

to support cell proliferation

$2.0B W/W market potential

Status: clinical study (first 20 subjects) – positive final results.

Additional 20 subjects - positive interim results

CE marking expected in 2016. In advanced discussions with global

orthobiologic and Sports Medicine companies to market in Europe

Indication: Treatment of tendinopathy (tendon inflammation)

by promoting healing of the tendon injury

14

Tennis elbow

3M+

Hand tendons

300K

Jumper’s knee

300K

Rotator cuff

400K

Achilles tendon

250K

ACL

200K

Annual procedures per indication

US market potential

http://www.aafp.org/afp/2007/0301/p701.html http://www.aaos.org/news/aaosnow/jan11/cover1.asp

http://www.achillestendon.com/Injuries.html

http://orthoinfo.aaos.org/topic.cfm?topic=a00297Prevalence of patellar tendinopathy in non-elite-athletes J. Zwerver,

S.W. Bredeweg, I. van den Akker-Scheek

Risk factors for hand-wrist disorders in repetitive work

F Thomsen, S Mikkelsen, J H Andersen

1515

PRP collection tubefrom any commercial PRP KitKit

16

clinical trial status

• 40 patients treated

• Final results with first 20 patients:

• At 3- months, 80% of the patients (N=20) reported

at least 25% reduction in PRTEE (improvement in

pain & functional disability) when compared to

baseline

• At 6- months, 90% of the patients (N=20) reported

at least a 25 % reduction in PRTEE scoring

17

1 Positive Effect of an Autologous Platelet Concentrate in Lateral Epicondylitis in Double-Blind Randomized Controlled Trial. Platelet-Rich Plasma versus

Corticosteroid injection with a 1-year follow up. Peerbooms et Al The America Journal of Sports Medicine Vol. 38 No 2 2010

48

67

80

36

68

90

0

10

20

30

40

50

60

70

80

90

100

Steroids PRP Vergenix STR

Patients Success Rate (%) (Improvement of 25 % in pain and motion1)

3-month 6-month

– Comparison to Standard of Care

Soft

Tis

sue

Injectable, Matrix, Membrane for tendon, Cartilage and Meniscus Repair

2012 2013 2014 2015 2016

18

Composition: rhCollagen and ceramic granules, in combination with

bio-functional molecules

Indications: Trauma and spinal fusion

$3.0B potential w/w market ($1.5B for spine* & $1.5B for trauma)

Scaffold for cell proliferation and controlled release of growth factor

for bone regeneration

Scaffold degradation synchronized with tissue growth

Status: preclinical studies

Bone Void Filler + growth factor

* Source: The Global Orthobiologics Market: Players, products and technologies driving change - 2008 Espicom Business Intelligence

$1.7M of development support from strategic partner in 2015, similar

commitment in 2016

19

July 12, 2015 -- CollPlant announced today that it has signed a non-binding

term sheet with a leading U.S company in the field of orthobiologics, for the

further development, and commercialization and supply of a novel

absorbable bio-active surgical matrix intended for use in spinal fusion and

trauma applications.

Upon execution of a definitive agreement, CollPlant will receive milestones

payments for the license to use its technology, and single-digit royalty

payments for future global sales.

The U.S company will participate in costs associated with the building of a

new CollPlant manufacturing facility for the production of rhCollagen and

the product.

CollPlant executes non-binding term sheet with leading US partner

20

Covers a broad range of bone fractures

Fixation

Synthetic substitutes

Allografts

Autografts

Vergenix™BVF

BASIC

FRACTURES

NON-UNION

FRACTURESBone injury severity scale

21

Wound filler

Indications: Chronic vascular ulcers, diabetic, pressure, venous and

surgical wounds

Pig studies showed VergenixTM FG superior to market leader

Scaffold for cellular infiltration and capillary growth to promote optimal

wound healing

$3B potential market ($500M ulcers only)

Clinical study (20 subjects) – positive final results

CE marking received in February, 2016

Product launch in Europe – in process

Source: "Worldwide Wound Management, 2008-2017: Established and Emerging Products, Technologies and Markets

in the U.S., Europe, Japan and Rest of World"

22

Company’s immediate report dated November 26, 2015 [MAGNA 2015-01-164958].

Patient 1 Day 0Day 28

(wound closed)

Patient 3 Day 0Day 28

(wound closed)

Patient 2 Day 0Day 28

(wound closed)

Clinical trial - Final resultsFull wound closure after 4 weeks

• Final results show average wound closure rates of 80% at 4 weeks

• Full wound closure was observed in nine of the 20 patients (45%) after 4 weeks following

a single administration unlike current standard of care requiring multiple treatments

23Future opportunities

Surgical wounds

rhCollagen-AM matrix intended for the

management of surgical and trauma

wounds

Source: Murphy and Atala, Nature Biotech, 2014

3D bioprinting is being applied to regenerative medicine to address the need

for complex scaffolds, or for tissues and organs suitable for transplantation

3D Bioprinting

with rhCollagen-based BioInk

Tendon repair

injectable rhCollagen/PRP matrix

intended for treatment of partial or

full tendon tears (ACL, RCR etc.)

24CollPlant IP portfolio

Patent Name Application #Priority

DatePatent Status

Collagen Producing Plants and Methods

of Generating and Using SameWO2006/035442 9/2004

National Phase: USA (CIP -DIV), Brazil, Europe(DIV),

India(DIV)

Granted: USA(CIP), Europe, Europe(DIV) (allowed), Hong

Kong ,Hong Kong(DIV) ,Canada, Japan Japan(DIV), Australia

(DIV-1), Australia (DIV-2), Mexico, China, South Africa, ,

Singapore, India, Israel, New Zealand.

Compositions Comprising Fibrous

Polypeptides and PolysaccharidesWO2009069123 11/2007

National Phase: Israel(DIV), Japan(DIV), USA(DIV-3)

Granted: USA,USA(DIV-1), USA(DIV-2), Australia,

Israel(Allowed),Europe(Allowed)

Methods of Generating Collagen Fibers WO2011/064773 11/2009 National Phase: Europe, USA, Hong Kong

Methods of Generating and Using

ProcollagenWO2009/128076 4/2008

National Phase:Europe, Canada, China(DIV), India, Israel

Granted: USA(Allowed)

Methods of Processing Recombinant

ProcollagenWO2009/053985 10/2007 Granted: USA, Israel, Europe

Compositions comprising collagen and

PRP for tissue regenerationWO2014/147622 3/2013 PCT (Published)

Cross-linked Resilin-containing materials W2015/068160 1/2013 PCT (Published)

Adhesive biopolymers and uses thereof WO2013/030840 9/2011 National Phase: USA, Europe, Israel

25

Sign a definitive License & Supply agreement with our U.S.

strategic partner, regarding Vergenix BVF product

Final clinical results for the Vergenix STR (40 patients)

Vergenix STR CE mark achievement

Vergenix FG Distribution agreement

Vergenix™STR Distribution agreement

VergenixSTR – first sales

VergenixFG – first sales

Sign with another strategic collaborator

Anticipated 12 month milestones

26

CollPlant investment highlights

Only viable technology currently available that can produce

truly human collagen

Multi-billion dollar market: innovative rhCollagen products

initially aimed at orthopedics and wound healing

Near-term revenues: U.S. strategic collaborator license and

commercialization of two lead products in Europe in 2016

Broadly applicable technology: future indications may include

BioInk for 3D Bioprinting, ACL repair and surgical wounds

Strong IP position

Proven management team